Maryland 2023 Regular Session

Maryland House Bill HB956 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4	[Brackets] indicate matter deleted from existing law.
5	5	hb0956
6	6
7	7	HOUSE BILL 956
8	8	J1 3lr0719
9	9	HB 1335/22 – HGO
10	10	By: Delegate Williams
11	11	Introduced and read first time: February 10, 2023
12	12	Assigned to: Health and Government Operations
13	13
14	14	A BILL ENTITLED
15	15
16	16	AN ACT concerning 1
17	17
18	18	Pregnant and Perinatal Drug Screening and Testing Workgroup 2
19	19
20	20	FOR the purpose of requiring the Secretary of Health to establish a Pregnant and Perinatal 3
21	21	Drug Screening and Testing Workgroup to study and make recommendations 4
22	22	relating to drug screening and testing of pregnant and perinatal patients and 5
23	23	newborn infants; and generally relating to the Pregnant and Perinatal Drug 6
24	24	Screening and Testing Workgroup. 7
25	25
26	26	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEM BLY OF MARYLAND, 8
27	27	That: 9
28	28
29	29	(a) The Secretary of Health shall establish a Pregnant and Perinatal Drug 10
30	30	Screening and Testing Workgroup. 11
31	31
32	32	(b) The Workgroup shall include: 12
33	33
34	34	(1) one representative of the Office of the Public Defender; 13
35	35
36	36	(2) one representative of the Maryland Hospital Association; 14
37	37
38	38	(3) one representative of the Maryland Patient Safety Center; 15
39	39
40	40	(4) one representative of the Department of Human Services, who is a 16
41	41	health care provider licensed in the State and has experience working with pregnant 17
42	42	women with substance use disorders and substance exposed newborns; 18
43	43
44	44	(5) one physician licensed in the State with expertise working with 19
45	45	pregnant and perinatal women with substance use disorders; and 20
46	46
47	47	(6) one pediatrician licensed in the State with expertise working with 21
48	48	substance exposed newborns. 22 2 HOUSE BILL 956
49	49
50	50
51	51
52	52	(c) The Workgroup shall: 1
53	53
54	54	(1) research current practices for drug screening and testing of pregnant or 2
55	55	perinatal patients in the State and across care settings; 3
56	56
57	57	(2) study evidence–based practices for drug screening and testing of 4
58	58	pregnant or perinatal patients and newborn infants, including obtaining informed consent 5
59	59	for drug screening and testing pregnant or perinatal patients and newborn infants; 6
60	60
61	61	(3) study each step in the process of identifying, referring, and removing 7
62	62	newborn infants who are born substance exposed; 8
63	63
64	64	(4) review statewide data regarding: 9
65	65
66	66	(i) the number of substance exposed newborn infants born each 10
67	67	year; 11
68	68
69	69	(ii) the most common types of substances identified as substances to 12
70	70	which the newborn infants were exposed; and 13
71	71
72	72	(iii) the rate of removal of substance exposed newborn infants to an 14
73	73	out of home setting; 15
74	74
75	75	(5) conduct a racial equity impact assessment on the current removal 16
76	76	process for substance exposed newborn infants and accompanying data; and 17
77	77
78	78	(6) make recommendations on: 18
79	79
80	80	(i) the dissemination of best practices for drug screening and testing 19
81	81	of pregnant or perinatal patients and newborn infants to physicians and hospitals that have 20
82	82	labor and delivery units and other health care settings where pregnant and perinatal 21
83	83	patients receive care; 22
84	84
85	85	(ii) the development and implementation of a universal consent form 23
86	86	specifically for the purpose of obtaining the consent of a pregnant or perinatal patient for 24
87	87	testing the pregnant or perinatal patient or a newborn infant for alcohol and substances 25
88	88	when medically necessary; and 26
89	89
90	90	(iii) the development and dissemination of educational materials for 27
91	91	perinatal and pregnant patients regarding drug screening, drug testing, and the process 28
92	92	following a positive drug screen or toxicology test. 29
93	93
94	94	(d) On or before December 1, 2024, the Workgroup shall report its findings and 30
95	95	recommendations to the Senate Finance Committee and the House Health and 31
96	96	Government Operations Committee, in accordance with § 2–1257 of the State Government 32
97	97	Article. 33 HOUSE BILL 956 3
98	98
99	99
100	100
101	101	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1
102	102	1, 2023. It shall remain effective for a period of 2 years and, at the end of June 30, 2025, 2
103	103	this Act, with no further action required by the General Assembly, shall be abrogated and 3
104	104	of no further force and effect. 4
105	105
106	106